DT
HealthMore in Health→
Phase 2 trial reports strong signal for FGFR inhibitor in SDH-deficient GIST
Key Takeaways
- Ten of 24 patients had partial responses in the phase 2 trial.
- Median progression-free survival reached 31.0 months.
- The drug targets an FGFR1-driven loop linked to SDH-loss biology.
DE
DT Editorial Team··via nature.com